Human growth hormone in bone regeneration of non-healing fractures

Koskinen, Erkki; Nieminen, R. A.; R, Lindholm; Puranen, Jaakko; Attila, U.

doi:10.1007/bf02064151

Cited by 5 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Human GH was administered at a dose of 16 IU, approximately 5 mg, on alternate days to 20 patients admitted with long bone nonunion or delayed union after a fracture. The study reported 100% healing rate, with 85% of the fractures considered stable within 12 weeks [135]. GH was also administered at the same dose to 12 patients with lower leg fractures for a period of 5 weeks, but the healing response did not appear to differ from that of the eight patients in the control group [134].…”

Section: Human Studiesmentioning

confidence: 96%

“…The first interventional studies aimed at evaluating fracture healing with the use of GH were reported in 1977 with a case control study on the effect of GH on fresh fractures [134] and a case series on nonhealing fractures [135]. Human GH was administered at a dose of 16 IU, approximately 5 mg, on alternate days to 20 patients admitted with long bone nonunion or delayed union after a fracture.…”

Section: Human Studiesmentioning

confidence: 99%

See 1 more Smart Citation

Growth hormone: does it have a therapeutic role in fracture healing?

Tran

Pagkalos

Tsiridis³

et al. 2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

Section: Human Studiesmentioning

confidence: 96%

Section: Human Studiesmentioning

confidence: 99%

Growth hormone: does it have a therapeutic role in fracture healing?

Tran

Pagkalos

Tsiridis³

et al. 2009

Expert Opinion on Investigational Drugs

View full text Add to dashboard Cite

show abstract

Roentgen cephalometric studies on skull development in rats. III. Gigantism versus acromegaly: Age differences in response to prolonged growth hormone administration

Savostin-Asling

Nakaiye

1980

Anat. Rec.

View full text Add to dashboard Cite

Experimental conditions simulating the induction of clinical pituitary gigantism and acromegaly were established by prolonged administration of growth hormone in high dosage to adult male rats starting at two different ages: 6 months (growth still active) and 14 1/2 months (growth virtually arrested). Treatment continued for 14 1/2 months, control receiving saline injections. Each group numbered eight at onset. Standardized x-rays of skull were made in ventro-dorsal and lateral planes, at onset, mid-period, and end of the study. Representative dimensions of cranial and facial segments were measured, including lengths, widths, palate dimensions, gnathic and interzygomatic angles, and incisor curvature. Some related indices were calculated. Means and standard errors were computed, usually on five to eight rats (oldest controls: three only). The response pattern of overall skull length was most illustrative. Younger adult controls grew actively until 14 months of age (5%) while injected rats grew still faster (8%); thereafter, controls grew negligibly (1%) and injected rats only slightly (2%). Older controls showed negligible skull elongation from 14 1/2 to 29 months of age, and growth hormone stimulated no gain. In the younger group, skull length gains were almost entirely in the facial region; cranium gained no length and widened only slightly. Cranial index increased slightly with the hormone. Facial (bizygomatic) width increased in both injected groups--proportionately in younger rats(to giganntism) and disproportionately in older rats. Palatal and dental growth followed facial patterns in both groups. Cranial vault bones thickened and, in older rats, developed surface irregularities, giving them a more massive, acromegaloid structure.

show abstract

Influence of bone and soft-tissue operations on serum concentrations of growth hormone, somatomedin C and alkaline phosphatase

Casser¹,

Zilkens²,

Forst³

et al. 1990

Arch Orthop Trauma Surg

View full text Add to dashboard Cite

After animal experiments suggested there was an interaction between growth hormone and bone healing, our aim in this paper was to ascertain whether there were any changes or possible interaction between the serum level of growth hormone, somatomedin C and alkaline phosphatase while a fractured bone was healing. To this end, the serum concentrations of growth hormone, somatomedin C, alkaline phosphatase and calcium were ascertained both pre- and post-operatively in two groups of patients--one with bone operations, the other with soft-tissue operations--and the results were compared. Comparing the groups, we found that after bone operations there was no increase in the serum level of growth hormone, nor of somatomedin C. An increase would have implied that these two hormones are directly involved in bone regeneration. There was no change in the serum level of alkaline phosphatase or calcium after either bone or soft-tissue operations.

show abstract

Human growth hormone in bone regeneration of non-healing fractures

Cited by 5 publications

References 5 publications

Growth hormone: does it have a therapeutic role in fracture healing?

Growth hormone: does it have a therapeutic role in fracture healing?

Roentgen cephalometric studies on skull development in rats. III. Gigantism versus acromegaly: Age differences in response to prolonged growth hormone administration

Influence of bone and soft-tissue operations on serum concentrations of growth hormone, somatomedin C and alkaline phosphatase

Contact Info

Product

Resources

About